Literature DB >> 24042031

Heterogeneity in intratumor correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors.

Tyler J Bradshaw1, Stephen R Bowen, Ngoneh Jallow, Lisa J Forrest, Robert Jeraj.   

Abstract

UNLABELLED: Intratumor heterogeneity in biologic properties and in relationships between various phenotypes may present a challenge for biologically targeted therapies. Understanding the relationships between different phenotypes in individual tumor types could help inform treatment selection. The goal of this study was to characterize spatial correlations of glucose metabolism, proliferation, and hypoxia in 2 histologic types of tumors.
METHODS: Twenty canine veterinary patients with spontaneously occurring sinonasal tumors (13 carcinomas and 7 sarcomas) were imaged with (18)F-FDG, (18)F-labeled 3'-deoxy-3'-fluorothymidine ((18)F-FLT), and (61)Cu-labeled diacetyl-bis(N(4)-methylthiosemicarbazone) ((61)Cu-ATSM) PET/CT on 3 consecutive days. Precise positioning and immobilization techniques coupled with anesthesia enabled motionless scans with repeatable positioning. Standardized uptake values (SUVs) of gross sarcoma and carcinoma volumes were compared by use of Mann-Whitney U tests. Patient images were rigidly registered together, and intratumor tracer uptake distributions were compared. Voxel-based Spearman correlation coefficients were used to quantify intertracer correlations, and the correlation coefficients of sarcomas and carcinomas were compared. The relative overlap of the highest uptake volumes of the 3 tracers was quantified, and the values were compared for sarcomas and carcinomas.
RESULTS: Large degrees of heterogeneity in SUV measures and phenotype correlations were observed. Carcinoma and sarcoma tumors differed significantly in SUV measures, with carcinoma tumors having significantly higher (18)F-FDG maximum SUVs than sarcoma tumors (11.1 vs. 5.0; P = 0.01) as well as higher (61)Cu-ATSM mean SUVs (2.6 vs. 1.2; P = 0.02). Carcinomas had significantly higher population-averaged Spearman correlation coefficients than sarcomas in comparisons of (18)F-FDG and (18)F-FLT (0.80 vs. 0.61; P = 0.02), (18)F-FLT and (61)Cu-ATSM (0.83 vs. 0.38; P < 0.0001), and (18)F-FDG and (61)Cu-ATSM (0.82 vs. 0.69; P = 0.04). Additionally, the highest uptake volumes of the 3 tracers had significantly greater overlap in carcinomas than in sarcomas.
CONCLUSION: The relationships of glucose metabolism, proliferation, and hypoxia were heterogeneous across different tumors, with carcinomas tending to have high correlations and sarcomas having low correlations. Consequently, canine carcinoma tumors are robust targets for therapies that target a single biologic property, whereas sarcoma tumors may not be well suited for such therapies. Histology-specific PET correlations have far-reaching implications for the robustness of biologic target definition.

Entities:  

Keywords:  18F-FDG; 18F-FLT; 61Cu-ATSM; dose painting; heterogeneity

Mesh:

Substances:

Year:  2013        PMID: 24042031      PMCID: PMC3974156          DOI: 10.2967/jnumed.113.121921

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  30 in total

Review 1.  Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality.

Authors:  C C Ling; J Humm; S Larson; H Amols; Z Fuks; S Leibel; J A Koutcher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-06-01       Impact factor: 7.038

Review 2.  The role of hypoxia-induced factors in tumor progression.

Authors:  Peter Vaupel
Journal:  Oncologist       Date:  2004

3.  Factors influencing [F-18] 2-fluoro-2-deoxy-D-glucose (F-18 FDG) uptake in melanoma cells: the role of proliferation rate, viability, glucose transporter expression and hexokinase activity.

Authors:  Kiyoshi Yamada; Ingo Brink; Emmanuel Bissé; Thomas Epting; Rupert Engelhardt
Journal:  J Dermatol       Date:  2005-05       Impact factor: 4.005

4.  Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).

Authors:  Hong Yuan; Thies Schroeder; James E Bowsher; Laurence W Hedlund; Terence Wong; Mark W Dewhirst
Journal:  J Nucl Med       Date:  2006-06       Impact factor: 10.057

5.  Gene expression profiling of human sarcomas: insights into sarcoma biology.

Authors:  Kristin Baird; Sean Davis; Cristina R Antonescu; Ursula L Harper; Robert L Walker; Yidong Chen; Arthur A Glatfelter; Paul H Duray; Paul S Meltzer
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

6.  Prognosis of canine patients with nasal tumors according to modified clinical stages based on computed tomography: a retrospective study.

Authors:  Yumi Kondo; Satoru Matsunaga; Manabu Mochizuki; Tsuyoshi Kadosawa; Takayuki Nakagawa; Ryohei Nishimura; Nobuo Sasaki
Journal:  J Vet Med Sci       Date:  2008-03       Impact factor: 1.267

7.  Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging.

Authors:  Joseph G Rajendran; David A Mankoff; Finbarr O'Sullivan; Lanell M Peterson; David L Schwartz; Ernest U Conrad; Alexander M Spence; Mark Muzi; D Greg Farwell; Kenneth A Krohn
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

8.  Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx.

Authors:  Matthew J Nyflot; Paul M Harari; Stephen Yip; Scott B Perlman; Robert Jeraj
Journal:  Radiother Oncol       Date:  2012-10-13       Impact factor: 6.280

Review 9.  Spontaneous and genetically engineered animal models; use in preclinical cancer drug development.

Authors:  K Hansen; C Khanna
Journal:  Eur J Cancer       Date:  2004-04       Impact factor: 9.162

Review 10.  The clinical approach towards chondrosarcoma.

Authors:  Hans Gelderblom; Pancras C W Hogendoorn; Sander D Dijkstra; Carla S van Rijswijk; Augustinus D Krol; Antonie H M Taminiau; Judith V M G Bovée
Journal:  Oncologist       Date:  2008-03
View more
  11 in total

Review 1.  Defining the Value of a Comparative Approach to Cancer Drug Development.

Authors:  Amy K LeBlanc; Christina N Mazcko; Chand Khanna
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

2.  Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy.

Authors:  Tyler J Bradshaw; Stephen Yip; Ngoneh Jallow; Lisa J Forrest; Robert Jeraj
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-28       Impact factor: 7.038

3.  The promise of multiparametric imaging in oncology: how do we move forward?

Authors:  Aniek J G Even; Dirk De Ruysscher; Wouter van Elmpt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-29       Impact factor: 9.236

4.  A Novel Framework for Automated Segmentation and Labeling of Homogeneous Versus Heterogeneous Lung Tumors in [18F]FDG-PET Imaging.

Authors:  Motahare Soufi; Alireza Kamali-Asl; Parham Geramifar; Arman Rahmim
Journal:  Mol Imaging Biol       Date:  2017-06       Impact factor: 3.488

5.  An alternative approach to histopathological validation of PET imaging for radiation therapy image-guidance: a proof of concept.

Authors:  Marian Axente; Jun He; Christopher P Bass; Gobalakrishnan Sundaresan; Jamal Zweit; Jeffrey F Williamson; Andrei Pugachev
Journal:  Radiother Oncol       Date:  2014-01-30       Impact factor: 6.280

Review 6.  Evaluation of hypoxia with copper-labeled diacetyl-bis(N-methylthiosemicarbazone).

Authors:  Suzanne E Lapi; Jason S Lewis; Farrokh Dehdashti
Journal:  Semin Nucl Med       Date:  2015-03       Impact factor: 4.446

7.  Imaging and dosimetric errors in 4D PET/CT-guided radiotherapy from patient-specific respiratory patterns: a dynamic motion phantom end-to-end study.

Authors:  S R Bowen; M J Nyflot; C Herrmann; C M Groh; J Meyer; S D Wollenweber; C W Stearns; P E Kinahan; G A Sandison
Journal:  Phys Med Biol       Date:  2015-04-17       Impact factor: 3.609

8.  Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation ((18)F-FDG, (64)Cu-ATSM and (18)F-FLT) in a Dog with Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring.

Authors:  Kamilla Westarp Zornhagen; Malene M Clausen; Anders E Hansen; Ian Law; Fintan J McEvoy; Svend A Engelholm; Andreas Kjær; Annemarie T Kristensen
Journal:  Diagnostics (Basel)       Date:  2015-09-11

9.  Micro Regional Heterogeneity of 64Cu-ATSM and 18F-FDG Uptake in Canine Soft Tissue Sarcomas: Relation to Cell Proliferation, Hypoxia and Glycolysis.

Authors:  Kamilla Westarp Zornhagen; Anders E Hansen; Jytte Oxboel; Andreas E Clemmensen; Henrik H El Ali; Annemarie T Kristensen; Andreas Kjær
Journal:  PLoS One       Date:  2015-10-26       Impact factor: 3.240

10.  Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.

Authors:  Wouter van Elmpt; Catharina M L Zegers; Bart Reymen; Aniek J G Even; Anne-Marie C Dingemans; Michel Oellers; Joachim E Wildberger; Felix M Mottaghy; Marco Das; Esther G C Troost; Philippe Lambin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.